NovoCure Ltd.
- Country
- 🇯🇪Jersey
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 1.4K
- Market Cap
- -
- Website
- http://www.novocure.com
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT06390059
- Locations
- 🇪🇸
University Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸University Hospital Foundation Jimenez Diaz, Madrid, Spain
🇪🇸Clara Campal Comprehensive Cancer Center (CIOCC), Madrid, Spain
TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT04717739
- Locations
- 🇩🇪
Universitätsklinikum Augsburg (AöR), Augsburg, Germany
🇩🇪Klinikum Chemnitz, Chemnitz, Germany
🇩🇪Universitätsklinikum des Saarlandes, Homburg, Germany
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 982
- Registration Number
- NCT04471844
- Locations
- 🇺🇸
Mary Bird Cancer Center Neuromedical Center, Baton Rouge, Louisiana, United States
🇺🇸Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Neuroscience Center, Philadelphia - University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04281576
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 540
- Registration Number
- NCT03940196
- Locations
- 🇺🇸
Center of Hope at Renown Medical Center, Reno, Nevada, United States
🇺🇸UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Minnesota Oncology Hematology, PA, Saint Paul, Minnesota, United States
TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03780569
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03606590
- Locations
- 🇨🇿
University Hospital Fakultni Nemocnice Olomouc, Oncology Clinic, Olomouc, Czechia
🇩🇪Ulm University Hospital, Ulm, Germany
🇫🇷CHU de Nantes, Nantes Cedex 01, France
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 571
- Registration Number
- NCT03377491
- Locations
- 🇦🇺
St. John of God Murdoch Hospital, Murdoch, Western Australia, Australia
🇦🇺Monash Medical Centre, Clayton, Australia
🇦🇺Sydney Adventist Hospital, Wahroonga, Australia
TTFields In GErmany in Routine Clinical Care
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 710
- Registration Number
- NCT03258021
- Locations
- 🇩🇪
Clinical center Aschaffenburg-Alzenau, Aschaffenburg, Bavaria, Germany
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
- Conditions
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT02397928
- Locations
- 🇵🇱
Katedra i Klinika Onkologii Uniwersytetu Medycznegi im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland
🇮🇹A.S.O. "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy
🇳🇱Erasmus Mc, Rotterdam, Netherlands